文献速递消化系统肿瘤

肝细胞癌免疫检查点阻断治疗现状综述

The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review.
PubMed 文献 · JAMA Oncol · 2021-01-01

本文综述了晚期肝细胞癌(HCC)系统治疗格局的快速演变,重点讨论免疫检查点阻断剂(ICB)在HCC中的应用前景与挑战,并探讨预测疗效或耐药的生物标志物需求。文中还讨论了两种靶向肿瘤免疫抑制的策略:已获验证的血管内皮生长因子通路抑制和正在研究中的转化生长因子-β通路抑制,以及它们重编程免疫抑制微环境、增强ICB疗效的原理与初步证据。

要点

  • 索拉非尼长期是晚期HCC唯一系统治疗选择,近年多种抗血管生成药物与ICB相继获批。
  • 贝伐珠单抗联合阿替利珠单抗的成功提示HCC一线治疗格局发生重要变化。
  • VEGF通路抑制已获验证、TGF-β通路抑制在研,二者均有望增强ICB疗效。

核心结论

  • 抗血管生成药物与ICB单用或联合的近期成败,为HCC新型系统治疗的实施提供了重要启示,并开辟了增强免疫治疗疗效的新途径。

研究设计与样本

  • 本文为综述,汇总ICB在HCC中应用的快速涌现的临床数据,并讨论预测疗效或耐药的生物标志物需求及两种靶向免疫抑制的策略。

主要发现

  • 过去十余年索拉非尼是晚期HCC唯一系统治疗选择,近年其他抗血管生成药物及多种ICB获批加入晚期HCC治疗手段。
  • 贝伐珠单抗联合阿替利珠单抗的近期成功,标志着HCC一线治疗的重要变化。

关键数值与推荐

  • 文中讨论的两种靶向肿瘤免疫抑制策略为:血管内皮生长因子通路抑制(已获验证)与转化型生长因子-β通路抑制(正在研究中)。

临床怎么用

  • 晚期HCC系统治疗选择已从索拉非尼单一方案扩展至多种抗血管生成药物与ICB;贝伐珠单抗联合阿替利珠单抗提示一线治疗新选择。

局限性

  • 预测ICB疗效或耐药的生物标志物仍属未满足的需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: For more than a decade, sorafenib has been the only systemic treatment option for patients with advanced hepatocellular carcinoma (HCC). However, rapid progress over the past few years led to approval of other angiogenesis inhibitors and several immune checkpoint blockers (ICBs) that have been added to the treatment armamentarium for advanced HCC. Moreover, the recent success of a combination of bevacizumab with atezolizumab signals an important change in the front-line treatment of HCC. OBSERVATIONS: This review summarizes rapidly emerging clinical data on the promise and challenges of implementing ICBs in HCC and discusses the unmet need of biomarkers to predict response or resistance to therapy. Two strategies to target immunosuppression in tumors are also discussed: one proven (vascular endothelial growth factor pathway inhibition) and one currently under investigation (transforming growth factor-β pathway inhibition). The rationale and preliminary evidence on how their inhibition may reprogram the immunosuppressive milieu and enhance the efficacy of ICBs in HCC are reviewed. CONCLUSION AND RELEVANCE: The recent successes and failures of angiogenesis inhibitors and ICBs, alone and in combination, have provided important insights into how to implement this novel systemic therapy in HCC and led to new avenues to enhance immunotherapy efficacy in this disease.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Pinter M, Jain RK, Duda DG, et al. The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review. JAMA Oncol. 2021. PMID: 33090190. doi:10.1001/jamaoncol.2020.3381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。